Duato Joaquin

CEO Duato Joaquin sold 100,000 JNJ shares in 2 transactions for $22.1M at $221.23 avg, reducing stake by 76.4%

Duato Joaquin, CEO and Chairman, executed 2 separate sales totaling 100,000 shares on 2026-01-26 for $22,122,893.44, reducing his post-transaction holdings to 30,852 shares from 130,852 shares (a -76.4% reduction). The sales occurred at a blended average price of $221.23 against a current market price of $227.72, meaning the stock has risen +0.0% from its 52-week high and +9.7% over the prior 30 days. His prior sell at JNJ on 2025-08-22 showed a 90-day return of +13.3%, indicating the stock rose after that sale, representing poorly-timed execution on the prior trade. The magnitude and concentration of this reduction—eliminating 76.4% of his holdings in a single filing—represents a substantial redeployment of the CEO's personal capital position in the company.

CEO Duato Joaquin sold 125,824 shares of JNJ for $22.5M on 2025-08-22, reducing stake by 31.3%

Duato Joaquin, CEO and Chairman, executed a substantial sale of 125,824 shares at $179.21 on 2025-08-22, reducing his post-transaction holdings from 401,791 to 275,967 shares—a 31.3% reduction in his position. The transaction valued at $22,548,654.81 occurred when the stock was near its 52-week high of $179.29, within 0.5% of that peak. The magnitude of this reduction—eliminating roughly one-third of his prior stake—is material and stands out relative to the company's scale: Johnson & Johnson carries a market cap of $429.7B and reported $23.7B in quarterly revenue with 18.96 P/E. The timing proximity to the 52-week high and the scale of position reduction merit investor review to understand any contextual drivers (scheduled plan, liquidity needs, or portfolio reallocation).